Valuation: Dimerix Limited

Market Cap 123M 88.22M 75.57M 70.71M 64.73M 121M 8.44B 835M 326M 4.24B 331M 324M 14.03B P/E 2024
-13.5x
P/E 2025 -24.3x
Enterprise Value 54.9M 39.35M 33.71M 31.54M 28.87M 54.18M 3.76B 373M 145M 1.89B 148M 145M 6.26B EV / Sales 2024
443x
EV / Sales 2025 49.4x
Free-Float
77.77%
Yield 2024 *
-
Yield 2025 -
1 day-4.62%
1 week+5.08%
Current month+26.53%
1 month+24.00%
3 months+51.22%
6 months-34.74%
Current year-43.64%
1 week 0.29
Extreme 0.29
0.33
1 month 0.24
Extreme 0.235
0.33
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 26/08/2018
Director of Finance/CFO 59 28/01/2026
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 61 02/07/2015
Chairman - -
Director/Board Member - 26/08/2018
Date Insider Type Main position Quantity % Market Cap.
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Director

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-4.62%+5.08%-31.87%+349.28% 133M
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average -0.06%+4.50%+70.33%+151.09% 27.66B
Weighted average by Cap. +0.48%+4.72%+99.51%+146.40%

Financials

2024 2025
Net sales 583K 418K 358K 335K 307K 576K 40.02M 3.96M 1.54M 20.1M 1.57M 1.54M 66.49M 5.59M 4M 3.43M 3.21M 2.94M 5.51M 383M 37.92M 14.79M 192M 15.04M 14.71M 637M
Net income -17.08M -12.24M -10.48M -9.81M -8.98M -16.85M -1.17B -116M -45.2M -588M -45.96M -44.96M -1.95B -13.25M -9.5M -8.14M -7.61M -6.97M -13.08M -909M -89.95M -35.08M -457M -35.67M -34.89M -1.51B
Net Debt -21.99M -15.76M -13.5M -12.63M -11.57M -21.71M -1.51B -149M -58.21M -758M -59.19M -57.9M -2.51B -68.19M -48.88M -41.87M -39.17M -35.86M -67.3M -4.68B -463M -180M -2.35B -184M -180M -7.77B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
21/08/26 A$0.3100 -4.62% 1,167,459
20/08/26 A$0.3250 +10.17% 2,234,026
19/08/26 A$0.2950 0.00% 946,121
18/08/26 A$0.2950 -1.67% 1,801,507
17/08/26 A$0.3000 +1.69% 2,122,482